Otoprotective effect of MnTBAP in cisplatin-induced hearing loss
PLOS One · 2026
DOI: 10.1371/journal.pone.0351911 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Shomaila Mehmood und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Environmental Health Sciences, Wayne State University, Detroit, Michigan, United States of America. Hauptthemen laut MEDLINE: Cisplatin, Hearing Loss, Metalloporphyrins, Antineoplastic Agents. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, NIDCD NIH HHS, NIH/NIDCD.
Abstract (Originalsprache)
Objective
Cisplatin, a life-saving chemotherapeutic drug, causes ototoxicity. Although sodium thiosulfate is used to prevent ototoxicity in pediatric patients, no other intervention has been approved for clinical use against cisplatin-induced hearing loss. Hence, there is an urgent need to identify drugs that prevent cisplatin ototoxicity.
Methods
CBA/J mice were treated with cisplatin (3 mg/kg, i.p., daily for 5 days), and MnTBAP (10 mg/kg, i.p., daily for 8 days) was used to inhibit cisplatin-induced ototoxicity. Auditory brainstem responses (ABRs) and distortion product otoacoustic emissions (DPOAEs) were recorded before and after treatment to assess hearing loss, while immunohistochemistry with anti-Myosin-VIIa was conducted to examine hair cell loss, with phalloidin to examine spiral ganglion neuron (SGN) loss, and with anti-nitrotyrosine to assess nitrotyrosine levels.
Results
Cisplatin treatment elevated the nitrotyrosine levels in hair cells and SGNs and increased the loss of these cells in the middle and basal cochlear regions. A negative correlation was observed between cisplatin-induced changes in the hair cell count or SGN density and nitrotyrosine levels. Cisplatin treatment elevated the hearing thresholds, as indicated by the ABRs, and lowered the DPOAE amplitudes, suggesting cisplatin-induced hearing loss. However, MnTBAP cotreatment prevented the cisplatin-induced changes in hearing sensitivity and reversed the morphological changes.
Conclusion
The otoprotection observed with MnTBAP cotreatment along with the attenuation of cisplatin-induced increase in nitrotyrosine levels in the cochlea indicates its potential as an inhibitor of cochlear nitrative stress and its utility in mitigating cisplatin-induced ototoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Environmental Health Sciences, Wayne State University, Detroit, Michigan, United States of America.
- Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan, United States of America.
ORCID-Profile: Pankaj Bhatia, Samson Jamesdaniel
Förderung
- NIEHS NIH HHS
- NIDCD NIH HHS
- NIH/NIDCD
Zitieren
APA
Mehmood, S., Bhatia, P., & Jamesdaniel, S. (2026). Otoprotective effect of MnTBAP in cisplatin-induced hearing loss. PLOS One. https://doi.org/10.1371/journal.pone.0351911
Vancouver
Mehmood S, Bhatia P, Jamesdaniel S. Otoprotective effect of MnTBAP in cisplatin-induced hearing loss. PLOS One. 2026. doi:10.1371/journal.pone.0351911
BibTeX
@article{Mehmood2026,
author = {Mehmood, Shomaila and Bhatia, Pankaj and Jamesdaniel, Samson},
title = {Otoprotective effect of MnTBAP in cisplatin-induced hearing loss},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0351911}
}
EUVIMED